RECOMBINANT HUMAN INTERLEUKIN-12 IN HIV INFECTED PTS

$0M01FY2000RRNIH

University Of North Carolina Chapel Hill, Chapel Hill NC

Investigators

Linked publications & trials

Paper 38599670 Paper 38236978 Paper 38160309 Paper 37910437 Paper 36738421 Paper 36691838 Paper 36540980 Paper 36396267 Paper 35582911 Paper 34998275 Paper 34911705 Paper 34841560 Paper 34453454 Paper 34370895 Paper 34042329 Paper 33901188 Paper 33591619 Paper 33152181 Paper 33066718 Paper 32813314 Paper 32773474 Paper 31631584 Paper 31498512 Paper 31134052 Paper 30864331 Paper 30771242 Paper 30642925 Paper 30481467 Paper 29847509 Paper 29461980 Paper 29361147 Paper 29316357 Paper 29273092 Paper 29218904 Paper 29193883 Paper 29171837 Paper 29135907 Paper 29099608 Paper 28989944 Paper 28264744 Paper 28225043 Paper 28215371 Paper 28099408 Paper 28098838 Paper 27524847 Paper 27509247 Paper 26991067 Paper 26776173 Paper 26575943 Paper 26270672 Paper 26230332 Paper 26180834 Paper 26148204 Paper 25959858 Paper 25933197 Paper 25884002 Paper 25778456 Paper 25727984 Paper 25461247 Paper 25415421 Paper 25377444 Paper 25257199 Paper 25199974 Paper 25159623 Paper 25157810 Paper 25109932 Paper 25079398 Paper 24999039 Paper 24925880 Paper 24922104 Paper 24920497 Paper 24834926 Paper 24729586 Paper 24713880 Paper 24707468 Paper 24702779 Paper 24692585 Paper 24671709 Paper 24659368 Paper 24602083 Paper 24577601 Paper 24568613 Paper 24557078 Paper 24548980 Paper 24531909 Paper 24509873 Paper 24360345 Paper 24300310 Paper 24260125 Paper 24253247 Paper 24231024 Paper 24166793 Paper 24147920 Paper 24144899 Paper 24038489 Paper 24010879 Paper 23982189 Paper 23973010 Paper 23950187 Paper 23944767

Abstract

ACTG 325: The purpose of this two-part study is to determine the safety and tolerance of several doses of rhIL-12, which will be given under the skin by injection. A total of thirty-six (36) people across the US with CD4 cell counts less than 50 cells/mm3 will participate in Part A, which will involve three different dose levels of rhIL-12 or matching placebo for 4 weeks. A total of twenty-seven (27) people with CD4 cell counts 300-500/mm3 will participate in Part B of the study, which will involve two different dose levels of rhIL-12 or matching placebo for four weeks. A total of 3-4 people will participate at UNC-CH.

View original record on NIH RePORTER →